including the best selling drugs in the entire year r rummira. the company expects this one drug to do 21 billion in sales and that isn't the most exciting start of the story four cents earnings beat up 14% year after year they went from midpoint of 647 up to $7.38. fabulous sales forecast. that translated into 32% earning growth the stocks going down, look it did rally up 14% in the wake of the number this is not some cyclical smokestack play that is expected to raise numbers when economy is booming. pharma outfits almost never pull extra dollar per share a lot of it comes from the fact that business is very strong cfo bill chase explained on the conference call, rummira is growing. -- that is up 28% from just last year and abbvie sees hepatitis c business doubling. and mega ret is there new hep c cure abbvie is the kind of drug stock that is worth buying as it goes lower. it is an opportunity even if the new initiative from jeff bassos seems to be a serious threat companies like abbvie should be fine stocks being pulled down because of etfs. et